Supplementary Table 1.
Patient Clinical and Pathologic Characteristics
| Patients | Age, y | Sex | Esophageal disease | Allergic diseases | Other diseases | Eos/HPF | Current treatment | Steroids |
|---|---|---|---|---|---|---|---|---|
| 1 | 9 | M | NL | None | None | 0 | - | |
| 2 | 11 | F | NL | None | None | 0 | - | |
| 3 | 12 | F | NL | None | None | 0 | - | |
| 4 | 9 | F | NL | None | None | 0 | - | |
| 5 | 4 | M | NL | None | None | 0 | - | |
| 6 | 13 | M | NL | None | None | 0 | Elimination diet | Nasocort, Flovent |
| 7 | 11 | M | NL | None | None | 0 | Food trial | - |
| 8 | 2 | M | EoE | None | None | 35 eos/HPF | Elimination | - |
| 9 | 9 | M | EoE | None | None | 40 eos/HPF | Elimination | - |
| 10 | 8 | M | EoE | None | None | 31 eos/HPF | Ad libitum | - |
| 11 | 10 | M | EoE | None | None | 41 eos/HPF | Ad libitum | Flovent (GlaxoSmithKline, Brentford, UK) |
| 12 | 12 | M | EoE | None | None | 63 eos/HPF | Elimination | Nasocort (Chattem, Inc, Chattanooga, TN) |
| 13 | EoE | None | None | 30 eos/HPF | - | Flovent | ||
| 14 | 3 | M | EoE | None | None | 30 Eos/HPF | Ad libitum | Pulmicort (AstraZeneca, Cambridge, UK) |
| 15 | 5 | M | EoE with dysphagia | None | None | 63 eos/HPF | - | Flovent |
| 16 | 10 | F | EoE with dysphagia | None | None | 80 eos/HPF | Ad libitum | - |
| 17 | 6 | M | EoE with dysphagia | None | None | 64 eos/HPF | - | Rhinocort (AstraZeneca), Flovent |
| 18 | 7 | M | EoE with dysphagia | None | Nonspecific colitis with focal cryptitis | 73 eos/HPF | Elimination | Flonase (GlaxoSmithKline) |
| 19 | 15 | M | EoE with dysphagia | None | None | 70 eos/HPF | Elimination | - |
| 20 | 8 | M | EoE with dysphagia | None | None | 50 eos/HPF | Ad libitum | - |
eos, eosinophils; F, female; M, male; NL, normal; HPF, high-power field.